Retatrutide vs tesamorelin: two peptides, two different targets
Retatrutide and tesamorelin are often mentioned together because they both affect fat. However, they have almost nothing in common: neither their mechanism of action, nor what studies have measured, nor their status. Here are their differences, point by point.
Tesamorelin 10 mg – €89.90R3 Reta 10 mg – €59.90
Comparison table
| Retatrutide | Tesamorelin | |
|---|---|---|
| Family | Triple incretin agonist | GHRH analogue |
| Targeted receptors | GLP-1, GIP and glucagon | GHRH receptor (pituitary gland) |
| Main effect measured | Overall weight loss | Reduction of visceral fat |
| Key result | Up to -24.2% of weight in 48 weeks (phase 2) | -15% visceral fat in 26 weeks, weight almost stable |
| Appetite | Greatly reduced | No noticeable effect |
| Schedule in the trials | Weekly injection | Daily injection |
| Status | In phase 3, no authorization | Authorized in the United States since 2010 (Egrifta), not in Europe |
| MyPeptide price | 10 mg: €59.90 (€5.99/mg) | 10 mg: €89.90 (€8.99/mg) |
Retatrutide in brief
Retatrutide activates three receptors simultaneously: GLP-1 and GIP, which affect appetite and insulin, and glucagon, which increases energy expenditure. In the phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., 338 participants), weight loss reached 24.2% over 48 weeks at the highest dose. A substudy also measured a significant reduction in liver fat. It is currently in phase 3 trials and is not yet approved in any country. For more information: retatrutide in France.
Tesamorelin in brief
Tesamorelin stimulates the pituitary gland, which then releases more growth hormone; this, in turn, promotes the release of stored fat, especially in the abdomen. In a trial published in the New England Journal of Medicine in 2007 (Falutz et al.), visceral fat decreased by 15% over 26 weeks, without significant weight loss. Details in our guide.
The real difference
- The retatrutide to lose weight : it reduces food intake and fat mass throughout the body.
- Tesamorelin mainly changes the distribution Fats: less visceral fat, without a noticeable decrease in weight.
- Both affect blood glucose, but in opposite directions: incretins like retatrutide lower it, growth hormone can raise it.
Can we study them together?
No published studies have combined retatrutide and tesamorelin. Their mechanisms of action are independent, but there are no clinical data on their combination. To compare retatrutide with another molecule in the same class, see retatrutide vs cagrilintide.
Price
Retatrutide 10 mg at €59.90 and Tesamorelin 10 mg at €89.90, lyophilized vials with published Janoshik analyses. Shipping from the European Union in 2 to 5 business days; free delivery on orders over €160.
Tesamorelin 10 mg – €89.90Retatrutide 10 mg – €59.90
- Tesamorelin: the complete guide
- Tesamorelin and visceral fat
- Tesamorelin and bodybuilding
- Side effects and reviews
- Our Janoshik (COA) analysis
Frequently asked questions
What is the difference between retatrutide and tesamorelin?
Retatrutide activates GLP-1, GIP and glucagon receptors and leads to overall weight loss; tesamorelin stimulates growth hormone and primarily reduces visceral fat, without significant weight loss.
Which one makes you lose the most weight?
Retatrutide: up to 24.2% of weight loss in 48 weeks in the phase 2 trial. Tesamorelin, on the other hand, leaves weight almost stable and acts on belly fat.
Can retatrutide and tesamorelin be combined?
No published studies have combined them. Their mechanisms are independent, but there is no clinical data on their combination.
Which one is authorized?
Tesamorelin has been authorized in the United States since 2010 under the name Egrifta, but not in Europe. Retatrutide is still in phase 3 trials and is not authorized anywhere.
What is the price of retatrutide and tesamorelin?
At MyPeptide, retatrutide 10 mg is €59.90 and tesamorelin 10 mg is €89.90.
Sources: Jastreboff A.M. et al., N Engl J Med 2023; Falutz J. et al., N Engl J Med 2007; FDA, Egrifta information leaflet. MyPeptide products are intended for scientific laboratory research use only.
